Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 versus physician's choice in previously treated endometrial cancer
2023-504816-14-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in endometrial cancer (EC) and endometrial carcinosarcoma (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Planned start Mar 2024; status: authorised.
02
Drugs
sacituzumab tirumotecan
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on 2023-504816-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504816-14-00.